Innovent to seek China approval of high-dose obesity shot after Phase 3 hit

A high-dose version of Innovent Biologics’ obesity drug led to patients with moderate-to-severe disease losing 18.6% of their body weight in about a year and two months, according to data from a late-stage China-based trial ...